Citations

Clear

4 citation(s) found for "Amini, Arya".

CCTG BR.38: Consolidative use of radiotherapy to block (CURB2) oligoprogression in patients with metastatic non–small-cell lung cancer—A randomized phase III trial.
Tsai, CJillian , SUN, A, Bradbury, Penelope Ann, Schellenberg, Devin, Bahig, Houda, Fung, Andrea S. , Bissonnette, Jean‐Pierre , Das, Jeeban P. , Kidane, Biniam, Louie, Alexander V., Miccio, Joseph, Welliver, M.X., Varlotto, John M., Amini, Arya, Kelly, Ryan, Ding, Keyue , Gaudreau, Pierre-Olivier , Schellenberg, Devin , Bahig, Houda , Kidane, Biniam , Louie, Alexander V. , Miccio, Joseph A., Varlotto, John M. , Amini, Arya

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps8124 Get It

TPS8124 Background: Immune checkpoint inhibitor (ICI)–based regimens are standard first-line therapy for metastatic non–small-cell lung cancer (NSCLC) without actionable driver mutations; however, most patients experience disease progression within 12 months. A subset develop oligoprogression, defined by progression at a limited number of metastatic sites with otherwise controlled disease. Oligoprogression represents a therapeutic window in which local ablative therapy could be used to prolong disease control. In the prior phase II CURB trial, SBRT was shown to significantly prolong progression-free survival (PFS) in patients with oligoprogressive NSCLC. Methods: CCTG-BR38 is an international, multicenter, open-label, randomized phase III trial conducted through the NCI National Clinical Trials Network. Adults with stage IV NSCLC receiving first-line ICI ± chemotherapy who develop ≤5 extracranial oligoprogressive lesions are randomized 1:1 to: (1) switch to second-line standard systemic therapy or (2) SBRT (30 Gy in 3 fractions) to all oligoprogressive sites followed by continuation of the same first-line systemic therapy. Randomization is stratified by type of first-line systemic therapy (ICI alone vs ICI + chemotherapy), number of oligoprogressive lesions (1–2 vs 3–5), and ECOG performance status (0-1 vs 2). Patients with treated, stable brain metastases are eligible. Primary Endpoints: Dual primary endpoints are PFS and overall survival (OS). Secondary endpoints include safety (CTCAE v5.0), patient-reported adverse events (PRO-CTCAE), quality of life (EORTC QLQ-C30/LC13), and cost-effectiveness (EQ-5D-5L; Canadian sites). Optional blood and tissue collection for exploratory biomarker analyses are planned. Statistical Considerations: A total of 320 patients (160 per arm) will be enrolled. The sample size is based on detecting a HR of 0.7 for OS (an improvement in median OS from 10 to 14.3 months) with 80% power using a 1-sided 2% level test (the overall 1-sided 2.5% type I error will be assigned 2% to OS and 0.5% to PFS). Interim analyses for futility and efficacy are planned. Current Status: The trial was centrally activated on April 3, 2025. Accrual is ongoing across Canadian and US NCTN sites. Clinical trial information: NCT06686771 .
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology
Blitzblau, Rachel , Aasi, Sumaira Z. , Alam, Murad, Amini, Arya , Bibee, Kristin , Bolotin, Diana, DiMaio, Dominick J. , Farma, Jeffrey M. , Ghosh, Karthik, Harms, Kelly L. , LeBoeuf, Nicole R. , Lukens, John N. , Manber, Susan, Mark, Lawrence A. , Medina, Theresa , Nehal, Kishwer S. , Paragh, György , Patel, Tejesh , Rich, Jason T. , Shaha, Ashok R. , Sharma, Bhavina, Sokumbi, Yemi, Thomas, Valencia D., Tomblinson, Courtney M. , Venkat, Puja , Xu, Yaohui , Yu, Siegrid S., McCullough, Beth, Espinosa, Sara, Bordeaux, Jeremy S. , Chen, Pei-Ling , Contreras, Carlo M. , Donigan, Jessica M. , Medina, Theresa Michelle , Nghiem, Paul , Olino, Kelly L. , Park, Soohyung , Sharma, Bhavina, Srivastava, Divya , Yusuf, Mehran Behruj

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 15, 2025 | Volume: 23 | Issue: 1 | Pages: No page available

10.6004/jnccn.2025.0001 | PMID 39819674 Get It

Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma and affects an estimated 1,500 people annually in the United States. DFSP frequently exhibits extensive local infiltration. Initial treatment is through surgical excision, and care should be taken to ensure that negative margins are achieved to minimize recurrence. Although DFSP has a reported high rate of recurrence, metastasis is more uncommon. Fibrosarcomatous DFSP is an aggressive variant with an increased risk for local recurrence and metastasis. If achieving negative margins or resection is not feasible, radiation therapy or systemic treatment are options that may be considered by a multidisciplinary team. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline recommended treatment options available for DFSP.
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024
Schmults, Chrysalyne D. , Blitzblau, Rachel , Aasi, Sumaira Z. , Alam, Murad , Amini, Arya , Bibee, Kristin , Bolotin, Diana, Chen, Pei-Ling , DiMaio, Dominick J. , Farma, Jeffrey M. , Ghosh, Karthik, Harms, Kelly L. , Lukens, John N. , Manber, Susan, Mark, Lawrence A. , Medina, Theresa , Nehal, Kishwer S. , Patel, Tejesh , Rich, Jason T. , Shaha, Ashok R. , Thomas, Valencia D., Tomblinson, Courtney M. , Venkat, Puja , Xu, Yaohui , Yu, Siegrid S., McCullough, Beth, Espinosa, Sara, Sekulić, Aleksandar , Alam, Murad , Bordeaux, Jeremy S. , Contreras, Carlo M. , Donigan, Jessica M. , Ho, Alan L. , Medina, Theresa Michelle , Nghiem, Paul , Olino, Kelly L. , Park, Soohyung , Puzanov, Igor , Sekulic, Aleksander , Srivastava, Divya , Tomblinson, Courtney, Yusuf, Mehran Behruj

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 19, 2024 | Volume: 22 | Issue: 1D | Pages: 1-11

10.6004/jnccn.2024.0002 | PMID 38244274 Get It

The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments from expert review from panel members, institutional review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled “Clinical N0 Disease, Locally Advanced MCC.” This new algorithm page addresses locally advanced disease, and the panel clarifies the meaning behind the term “nonsurgical” by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Schmults, Chrysalyne D. , Blitzblau, Rachel , Aasi, Sumaira Z. , Alam, Murad , Amini, Arya , Bibee, Kristin , Chen, Pei-Ling , DiMaio, Dominick J. , Farma, Jeffrey M. , Ghosh, Karthik, Harms, Kelly L. , Lukens, John N. , Mark, Lawrence A. , Medina, Theresa , Nehal, Kishwer S. , Patel, Tejesh , Rich, Jason T. , Sekulić, Aleksandar , Shaha, Ashok R. , Thomas, Valencia D., Tomblinson, Courtney M. , Venkat, Puja , Xu, Yaohui , Yu, Siegrid S., McCullough, Beth, Espinosa, Sara, Alam, Murad , Bordeaux, Jeremy S. , Contreras, Carlo M. , Donigan, Jessica M. , Ho, Alan L. , Medina, Theresa Michelle , Nghiem, Paul , Olino, Kelly L. , Park, Soohyung , Puzanov, Igor , Srivastava, Divya , Tomblinson, Courtney, Yusuf, Mehran Behruj

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 7, 2023 | Volume: 21 | Issue: 11 | Pages: 1181-1203

10.6004/jnccn.2023.0056 | PMID 37935106 Get It

Basal cell carcinoma (BCC) is the most common form of skin cancer in the United States. Due to the high frequency, BCC occurrences are not typically recorded, and annual rates of incidence can only be estimated. Current estimated rates are 2 million Americans affected annually, and this continues to rise. Exposure to radiation, from either sunlight or previous medical therapy, is a key player in BCC development. BCC is not as aggressive as other skin cancers because it is less likely to metastasize. However, surgery and radiation are prevalent treatment options, therefore disfigurement and limitation of function are significant considerations. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline an updated risk stratification and treatment options available for BCC.